Introduction 5
The ease of accessing high altitude above 2000 m presents an opportunity to gain a 6 greater insight into the acute responses to hypoxia [1, 2] . In this review, advances in the 7 pharmacologic prevention and treatment of high altitude illnesses are discussed, aiming to: 1) 8 evaluate currently used pharmacotherapies and 2) consider theoretical pharmacotherapies in light 9 of new discoveries. The following databases were searched (inception March 1) for relevant 10 studies focusing largely on literature produced after 2008: MEDLINE, PubMed, and Embase. 11
Search strategies utilized a set of keywords (with synonyms and closely related words) specific 12 to each section herein with additional studies identified by examining the reference list contained 13 from chosen studies. 14 The hypobaric hypoxic conditions at altitude elicit distinct temporary and reversible 15 physiologic responses in lowlanders who have spent a few hours to days at high altitude 16
(generally over 3,000 m). These repsonses are predominantly attributed to hypoxemia [3, 4] . 17
The initial physiologic acclimatisation is hyperventilation, which negates reductions in the partial 18 pressure of oxygen (PO 2 ) but also results in a greater loss of carbon dioxide (CO 2 ) (hypocapnia) 19 and subsequent respiratory alkalosis [5] . This respiratory alkalosis elicits a renal compensation 20 response by which the kidneys increase bicarbonate (HCO 3 -) excretion and increase hydrogen 21 (H + ) retention, resulting in a secondary metabolic acidosis and a mild diuretic effect [6, 7] . 22
Hypoxia also elicits an increase in sympathetic tone, an increase in blood pressure (BP), and an 23 its more limited tissue penetrance and near isolated effects on renal CA, Bz elicits fewer CNS-1 related side effects [38, 68] . 
Dexamethasone (Dx) 5
Recent reviews have highlighted the effects of Dx in its ability to prevent altitude 6 illnesses, which include: reductions in ROS formation, endogenous antioxidant upregulation, 7 sympatholysis, improved O 2 saturation, alteration of aquaporin expression, and HSP-70 and 8 adrenomedullin upregulation [36] . However, its use as a prophylactic agent could become 9 problematic for many reasons. Unlike Az, Dx does not permit the normal acclimatization 10 process to transpire. Additionally, if Dx is used as a prophylactic agent and is then abrubtly 11 discontinued during ascent, acute illness may set in. For this reason, its use as a prophylactic 12 treatment should be avoided when possible, and other drugs should be considered. 13
The clinical management of HACE is distinctly different. HACE is a medical emergency 14 requiring immediate attention, and is known to occur in those whom have already developed 15 AMS. Early treatment using Dx is the most effective [70] . An initial large dose of Dx is advised, 16 8 -10 mg by intramuscular or oral administration, followed by 4 mg every 6 hours [56] . 17 18
Inhaled Budesonide 19
Conflicting results have been produced concerning the efficacy of inhaled budesonide for 20 preventing and treating altitude illnesses. Administration of inhaled budesonide for 3 days prior 21 to ascent has been effective in preventing AMS in the first 20 hours of HA exposure [71] . 22
However, more recent research shows no significant reductions in AMS with budesonide 23 administration at various dosages nor has it shown the ability of budesonide to prevent AMS to 1 the same degree as Az [72, 73] . Budesonide is a drug that elicits isolated effects on the lung 2 tissue as opposed to eliciting a systemic effect, thus, its efficacy for the prophylactic treatment of 3 AMS may be limited. [74] . 4 5
Diuretics 6
Abnormal fluid balance has been repeatedly observed in those whom present with AMS 7 [75, 76] . While a degree of diuresis with hypoxic exposure is considered a normal response, 8 individuals who develop AMS demonstrate significantly greater fluid retention than those who 9 do not develop AMS [76] . Such diuresis at high altitude is also related to the ventilatory 10 response to hypoxia, such that, a blunted ventilatory response may result in a greater degree of 11 fluid retention and ensuing altitude illness [77, 78, 79, 80, 81] . Furthermore, such blunted 12 responses and associated fluid retention may promote the development of HAPE. Thus, the 13 maintenance of an appropriate fluid balance at high altitude, namely preventing a state of fluid 14 excess, is important for the prevention of all altitude-related illnesses [76, 82] . There is limited 15 information on the use of diuretics in preventing AMS except it has been shown that 16 spironolactone is ineffective in preventing AMS when compared to Az [83] . It is also possible 17 that those with AMS may be volume depleted, thus, the use of a loop diuretic in this instance 18 could be problematic. Herein lies the rationale behind furosemide being deamed as inappropriate 19 for the treatment of AMS which would produce excessive diuresis that may be dangerous at 20 altitude [62] . Spironolactone has also been considered for the treatment of altitude illnesses due 21 to the mild acidosis produced [83] . 22
Angiotensin Converting Enzyme (ACE) Inhibitors 1
Angiotensin converting enzyme (ACE), found predominantly in the pulmonary and renal 2 endothelia, plays a key role in the renin-angiotensin aldosterone system (RAAS). ACE 3 influences the control of systemic BP via its conversion of angiotensin-I to angiotensin-II (A-II) 4 and the subsequent downstream effects on fluid balance. The implications of ACE and 5 performance at altitude have been evaluated but the use of ACE inhibitors was not addressed 6
[84]. More recent discoveries surrouding genetic polymorphisms of the ACE gene and 7 associated responses to hypoxia have resulted in the consideration of ACE inhibitors for 8 prevention and treatment of altitude illnesses [85, 86] . As individuals with the "DD" genotype 9 appear to be at greater risk for maladaptations at altitude, inducing physiologic response that is 10 more consistent with a favorable II or ID genotype could be advantageous altitude [87] . 11
The effects of ACE inhibitors during exposure to hypoxia include blunting of the hypoxic 12 ventilatory response and reduction in PAPs [86, 88, 89] . Therefore, such drugs may reduce 13 HAPE in a similar way to that of nifedipine [86] . However, ACE inhibitors have been shown to 14 blunt the kidneys ability to produce eryhtoprpoetin and, thereby, producing an unwanted effect in 15 those attempting to acclimatize [90] . While the ventilatory responses to ACE inhibitors during 16 hypoxia have been briefly considered, further research is warranted in this area. Future research 17 should also consider the hormonal effects of ACE inhibitors with hypoxic exposure, such as the 18 influence on aldosterone and any subsequent relation to altitude illnesses. 19 20
Angiotensin-II Receptor Blockers (ARBs) 21
Intermittent hypoxia such as in sleep apnoea is accompanied by concomitant rises in BP, 22 which may be mediated by A-II [85, 91, 92]. ARBs, such as, telmisartan have been shown to 23 reduce increases in BP associated with ascent to altitude up to 3400 m in healthy individuals [93, 1 94, 95]. Additionally, losartan appears to alleviate the oxidative stress imposed by intermittent 2 hypoxia and may reduce ROS production [91]. Thus, ARBs may attenuate the progression of 3 altitude illnesses by regulating fluid volume, reducing altitude associated increases in BP, and 4 alleviating oxidative stress; however, their efficacy at extreme altitudes may be limited [91, 93] . 5
Furthermore, ARBs and ACE inhibitors are safe to administer at altitude but comparisons 6 between these drugs and existing pharmacologic strategies, such as Az, are warranted. 7 8
Magnesium 9
Magnesium is an antagonist of N-methyl-D-aspartate (NMDA). The involvement of the 10 N-methyl-D-aspartate (NMDA) receptor in regards to hypoxic altitude convulsions has 11 previously been implicated with a blockage of the NMDA receptor proving to have beneficial 12 effects [62, 96, 97] . Intravenous magnesium appears to be superior over oral administration for compared. Ibuprofen has been repeatedly shown to reduce HAH due to its anti-inflammatory 20 effects [100, 101, 102], which may also be responsible for its superiorty over paracetamol. 
Phosphodiesterase Inhibitors (PDE-5 Inhibitors) 8
Elevated PAPs are of concern in relation to altitude illnesses and can result in the There is evidence that acetazolamide inhibits HPV in many animal models and in humans 5 and, therefore, could be useful in the prevention, and perhaps treatment, of HAPE [123]. 6 7 4.4 Corticosteroids 8
Dexamethasone 9
While the treatment of HACE with Dx is recommended, its administration for the 10 treatment of HAPE is less established. Recent guidelines provide a Recommendation Grade of 11 2C for Dx as a preventative strategy for HAPE due to limited evidence, and suggest that it is 12 reserved for the clinical presentation of HAPE, known HAPE-susceptible individuals, or when 13 alternative therapies are contraindicated [56] . It is possible that Dx could reduce HAPE by 14 stimulating the cGMP production in response to hypoxia, increasing NOS activity and 15 modulating sympathetic activity; however,. limited reports have documented its use in this way 16 [118, 124, 125, 126] . 17 18
Iron Supplementation 19
The suggestion of iron supplementation for the treatment of altitude illnesses comes from 20 the effects that severe iron deficiency has on the pulmonary vasculature resulting in pulmonary 21 vasoconstriction [127] . Unfortunately, however, it seems that i.v. iron supplementation has no 22 significant protective effect against AMS [128]. 23 
Type A Endothelin Receptor Antagonists (ET A Receptor Antagonist) 6
The effects of hypoxia in pulmonary vasculature may be detrimental and result in a 7 greater propensity for apoptosis in the pulmonary artery smooth muscle cells [129] . Thus, 8 susceptibility to altitude-related illnesses attributed to such effects on the pulmonary vasculature 9
should kept in mind with the consideration of new pharmacotherapies for prevention and 10 treatment of altitude illnesses. 11
Type A endothelin receptor antagonists (ET A antagonists) elicit similar outcomes as 12 PDE-5 inhibitors on the pulmonary vasculature, however, the mechanism of action of ET A 13 antagonists is inherently different. In animal models, ET A antagonists have proven to be 14 beneficial in reduction of PAPs in the HAPE susceptible [31, 130, 131, 132, 133] . It has also 15 been hypothesized that additional off-target effects of ET A antagonists may be more beneficial 16
for the prophylactic treatment of altitude illnesses [65]. 17
Sitaxentan 18
Research has demonstrated that the ET A antagonist sitaxentan reduces pulmonary 19 vascular resistance (PVR) in both, acute and chronic hypoxia with such changes in PVR being 20 correlated with restorations in VO 2max [134] . Increases in PVR associated with hypoxia may be 21 a contributing factor to the reductions in VO 2max observed in hypoxia. Thus, sitaxentan, may 22 offer an alternative option to existing pharmacotherapies, especially, when exercise performance 23 at altitude is a priority. In vivo models have shown sitaxentanreduces high-altitude induced 1 cerebral vascular leakage by 40% but its effect on altitude illnesses remains uninvestigated [65]. were substantially downregulated and IL-17F and CCL8 were substantially upregulated in the 5 AMS group. This could be due to an enriched DUSP1 response to oxidative stress at altitude, 6 limiting the IL-10 production by adversely effecting p38 phosphorylation [145] . An additional 7 mechanism [145] is the downregulation of the CCR7 protein, a protein that maintains T-cell 8 function normal secretion of IL-10. Based on these findings there is substaintial evidence 9 implicating the involvement of the inflammatory response (anti-inflammatory response) in the 10 development of AMS.
This evidence also supports the consideration of alternative 11 pharmacologic agents that promote IL-10 upregulation for the prevention and treatment of 12 altitude illnesses. 13 14
Gabapentin 15
The use of alternative drugs that influence the upregulation of IL-10 may be more 16 appropriate as prophylactic agents. Gabapentin has been used to treat high altitude headache and 17 is now known to upregulate IL-10; however, the use of gabapentin to treat altitude illnesses has 18 not gained wide popularity [132, 149, 150, 151]. 19 [156]. Furthermore, no changes in VO 2max were reported with riociguat administration. This is 15 promising in view of recent research with concern for the potential cardiovascular effects and 16 exercise performance limitations amongst older individuals (e.g. 50+ years ) [49] . The efficacy 17 for the use of riociguat as a prophylactic agent against AMS or HAPE is unknown. 18 19
Rho-kinase Inhibitors

Oxyhaemoglobin Dissociation Influencers 20
Inducing a leftward shift in the oxyhaemoglobin dissociation curve could potentially 21 help prevent or reduce the risk of altitude illnesses [157] . 
Corticotropin-releasing Factor Antagonists 9
Corticotropin-releasing hormone (CRH), is a peptide hormone released from the 10 hypothalamus in response to stress resulting in the release of ACTH. CRH has been shown to 11 contribute to the brain-endocrine-immune network and associated dysfunction in altitude illness 12 [160] . Individuals that with AMS demonstrate enhanced plasma levels of CRH in response to 13 hypoxia induced by rapid ascent [161] . It is possible that enhanced plasma levels of CRH, which 14 activate the cAMP-dependent protein kinase pathway and calcium influx through L-type 15 channels, contributes to excessive vasoconstriction in response to hypoxia, thereby, promoting 16 AMS [161] . Over activation of the target receptor of CRH, the corticotropin releasing hormone 17 receptor-1 (CRHR1) in response to hypoxia has also been shown to contribute to increased 18 expression of aquaporin-4 (increasing cellular permeability), promoting cellular water influx and 19 cerebral oedema [25] . Therefore, drugs that block or produce antagonistic effects at the CRHR1 20 receptor may attenuate thishypoxic response . 21 The evolving understanding of pathophysiologies associated with altitude has enabled for 5 a more thorough evaluaion of existing pharmacotherapies used to prevent and treat altitude 6 illnesses and has allowed for the consideration of alternative options. When rapid ascent is 7 unavoidable, and immediate descent is impossible, established pharmacotherapies remain 8 important for preventing and managing altitude-related illnesses. Additional alternative agents 9 presented here offer a considerable expansion of existing pharmacotherapies for the future. 10 11
Expert opinion 12
The spectrum of acute altitude illnesses range from mild, self-limiting syndromes of 13 AMS and HAH, to more severe syndromes, such as HACE and HAPE. Pathophysiologic 14 changes that contribute to the development of AMS occur on a continuum with HACE, and thus, 15 treatment and prevention strategies for these acute altitude illnesses also occur along this 16 continuum. On the other hand, HAPE is attributed to an alternate pathophysiologic responses 17 and pharmacological treatments. 18
Slow ascent remains the primary prevention strategy for the development of altitude 19 illness, and rapid descent remains the primary treatment strategy for all altitude illness. 20
Pharmacologic agents aid in both the prevention and treatment of such illnesses. Pharmacologic 21 agents are particularly helpful when rapid ascent cannot be avoided or rapid descent is not 22 possible. Strikingly, after decades of research, these pharmacologic prevention and treatment 23 24 strategies have not changed wildly. Acetazolamide remains the pharmacologic agent of choice 1 for the prevention and treatment of AMS and HACE and appears to be effective in dosages as 2 little as 62.5 mg twice daily for preventation. Consideration should be given when prescribing 3
Az to adults over the age of 50 given the age-related reductions in kidney function and therefore 4 lower renal clearance of Az. Calcium-channel blockers and PDE-5 inhibitors remain the 5 pharmacologic agents of choice in the prevention and treatment of HAPE. Dexamethasone is 6 inappropriate for prophylaxis and should be reserved for the treatment of HACE. 7
Dexamethosone's efficacy for the treatment of HAPE remains unestablished; however, it should 8 not be forfeited as a treatment option in thise instance entirely, particularly, when alternative 9 treatment strategies may be contraindicated. 10
In light of the research advances that have been made in the last 10 years, current 11 evidence supports the potential inclusion of alternative and newer drugs for the prevention and 12 treatment of altitude illnesses. IL-10 upregulators may be helpful in preventing all altitude 13 related illnesses and particularly AMS. Corticotropin-releasing factor antagonists, glutathione S-14 transferase inducers and nootropics may be beneficial for prophylaxis and treatment of AMS, 15 specifically. Type A endothelin receptor antagonists, rho-kinase inhibitors, and guanylate 16 cyclase stimulators may serve as additive or alternative agents for prophylaxis and treatment of 17 HAPE. Agents that influence the oxyhaemoglobin dissociation curve may be beneficial in 18 preventing and treating all altitude illnesses. Further evaluation of the efficacy of these newer 19 treatment strategies is warranted. 20
Identification of those who are susceptible to altitude illnesses, as well as gaps in the 21 existing knowledge regarding the etiology of the development of these illnesses, are challenges 22 for the future. Ideally, an objective measure of AMS is required in addition to the Lake Louise 23 25 scoring system widely used in research studies. While the pharmacologic prevention and 1 treatments strategies discussed herein are warranted, future research should aim to elucidate the 2 importance of including genetic profiling prior to prescribing medication for those patients 3 wishing to sojourn to high altitude. Genetic profiling in this instance would allow for the 4 evaluation of gene expression and expression patterns that are consistent with (or may contribute 5 to the development of) those who have previously been observed to develop altitude illnesses. 6
This would allow not only for a risk evaluation and determination of susceptibility prior to 7 sojourn, but would also allow for the appropriate prescription of pharmacologic agents .. 8 Therefore, future pharmacologic research pertaining to the prevention and treatment of high 9 altitude medicine should be largely focused on personalized medicine and/or combination 10 treatments for the best outcomes. 11 
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